Deciphering the Arginine-Binding Preferences at the Substrate-Binding Groove of Ser/Thr Kinases by Computational Surface Mapping

Protein kinases are key signaling enzymes that catalyze the transfer of γ-phosphate from an ATP molecule to a phospho-accepting residue in the substrate. Unraveling the molecular features that govern the preference of kinases for particular residues flanking the phosphoacceptor is important for understanding kinase specificities toward their substrates and for designing substrate-like peptidic inhibitors. We applied ANCHORSmap, a new fragment-based computational approach for mapping amino acid side chains on protein surfaces, to predict and characterize the preference of kinases toward Arginine binding. We focus on positions P−2 and P−5, commonly occupied by Arginine (Arg) in substrates of basophilic Ser/Thr kinases. The method accurately identified all the P−2/P−5 Arg binding sites previously determined by X-ray crystallography and produced Arg preferences that corresponded to those experimentally found by peptide arrays. The predicted Arg-binding positions and their associated pockets were analyzed in terms of shape, physicochemical properties, amino acid composition, and in-silico mutagenesis, providing structural rationalization for previously unexplained trends in kinase preferences toward Arg moieties. This methodology sheds light on several kinases that were described in the literature as having non-trivial preferences for Arg, and provides some surprising departures from the prevailing views regarding residues that determine kinase specificity toward Arg. In particular, we found that the preference for a P−5 Arg is not necessarily governed by the 170/230 acidic pair, as was previously assumed, but by several different pairs of acidic residues, selected from positions 133, 169, and 230 (PKA numbering). The acidic residue at position 230 serves as a pivotal element in recognizing Arg from both the P−2 and P−5 positions.

[1]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[2]  A. Toker Signaling through protein kinase C. , 1998, Frontiers in bioscience : a journal and virtual library.

[3]  E. Krebs,et al.  Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase. , 1977, The Journal of biological chemistry.

[4]  D. Alessi,et al.  The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.

[5]  Susan S. Taylor,et al.  Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.

[6]  D. Tobi,et al.  Sequence-based Design of Kinase Inhibitors Applicable for Therapeutics and Target Identification* , 2004, Journal of Biological Chemistry.

[7]  Yu Xue,et al.  A summary of computational resources for protein phosphorylation. , 2010, Current protein & peptide science.

[8]  D. Higgins,et al.  T-Coffee: A novel method for fast and accurate multiple sequence alignment. , 2000, Journal of molecular biology.

[9]  M Pastor,et al.  A novel strategy for improving ligand selectivity in receptor-based drug design. , 1995, Journal of medicinal chemistry.

[10]  E. Krebs,et al.  Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. , 1991, The Journal of biological chemistry.

[11]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[12]  Johann Hofmann,et al.  The potential for isoenzyme‐selective modulation of protein kinase C , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P. Jennings,et al.  Coupling phosphoryl transfer and substrate interactions in protein kinases. , 2005, Biochimica et biophysica acta.

[14]  J. Herrero,et al.  Kinase peptide specificity: improved determination and relevance to protein phosphorylation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[16]  A. Levitzki,et al.  Novel method for the synthesis of urea backbone cyclic peptides using new Alloc‐protected glycine building units , 2010, Journal of peptide science : an official publication of the European Peptide Society.

[17]  M. Niv,et al.  Synthesis of a novel macrocyclic library: discovery of an IGF-1R inhibitor. , 2008, Journal of combinatorial chemistry.

[18]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[19]  Susan S. Taylor,et al.  cAMP‐dependent protein kinase: Crystallographic insights into substrate recognition and phosphotransfer , 1994, Protein science : a publication of the Protein Society.

[20]  Alan E. Mark,et al.  The GROMOS96 Manual and User Guide , 1996 .

[21]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Bruce Stillman,et al.  Deciphering Protein Kinase Specificity through Large-scale Analysis of Materials Supplemental Deciphering Protein Kinase Specificity through Large-scale Analysis of Yeast Phosphorylation Site Motifs , 2010 .

[23]  M. Eisenstein,et al.  Peptide inhibitors targeting protein kinases. , 2009, Current pharmaceutical design.

[24]  Eugene I Shakhnovich,et al.  Amino acids determining enzyme-substrate specificity in prokaryotic and eukaryotic protein kinases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[26]  R. Espinosa,et al.  Cloning and Characterization of MST4, a Novel Ste20-like Kinase* , 2001, The Journal of Biological Chemistry.

[27]  M. Khrestchatisky,et al.  Synthetic therapeutic peptides: science and market. , 2010, Drug discovery today.

[28]  R. Pearson,et al.  Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. , 1991, Methods in enzymology.

[29]  D. Fairlie,et al.  A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.

[30]  Zhou Songyang,et al.  Use of an oriented peptide library to determine the optimal substrates of protein kinases , 1994, Current Biology.

[31]  Susan S. Taylor,et al.  Synergistic Binding of Nucleotides and Inhibitors to cAMP-dependent Protein Kinase Examined by Acrylodan Fluorescence Spectroscopy* , 1997, The Journal of Biological Chemistry.

[32]  Bostjan Kobe,et al.  Predikin and PredikinDB: a computational framework for the prediction of protein kinase peptide specificity and an associated database of phosphorylation sites , 2008, BMC Bioinformatics.

[33]  Stefan Knapp,et al.  Structure and Substrate Specificity of the Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[34]  S. Taylor,et al.  Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Fabbro,et al.  Structural biology contributions to tyrosine kinase drug discovery. , 2009, Current opinion in cell biology.

[36]  Debasisa Mohanty,et al.  Identification of substrates for Ser/Thr kinases using residue-based statistical pair potentials , 2010, Bioinform..

[37]  Joost Schymkowitz,et al.  Computational design of peptide ligands. , 2011, Trends in biotechnology.

[38]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[39]  Adrian L Gill,et al.  A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.

[40]  Yanli Wang,et al.  Multiple intermolecular interaction modes of positively charged residues with adenine in ATP-binding proteins. , 2003, Journal of the American Chemical Society.

[41]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[42]  Eduardo Garcia Urdiales,et al.  Accurate Prediction of Peptide Binding Sites on Protein Surfaces , 2009, PLoS Comput. Biol..

[43]  Paramjit S. Arora,et al.  An Orthosteric Inhibitor of the Ras-Sos Interaction , 2011, Nature chemical biology.

[44]  R. Vaillancourt,et al.  MAP3Ks as central regulators of cell fate during development , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[45]  Stephen Shaw,et al.  A Single Pair of Acidic Residues in the Kinase Major Groove Mediates Strong Substrate Preference for P-2 or P-5 Arginine in the AGC, CAMK, and STE Kinase Families* , 2005, Journal of Biological Chemistry.

[46]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[47]  Harel Weinstein,et al.  A flexible docking procedure for the exploration of peptide binding selectivity to known structures and homology models of PDZ domains. , 2005, Journal of the American Chemical Society.

[48]  Tamotsu Noguchi,et al.  PDB-REPRDB: a database of representative protein chains from the Protein Data Bank (PDB) in 2003 , 2003, Nucleic Acids Res..

[49]  Susan S. Taylor,et al.  2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. , 1993, Acta crystallographica. Section D, Biological crystallography.

[50]  M. Niv,et al.  Prevention of insulin resistance and beta‐cell loss by abrogating PKCε‐induced serine phosphorylation of muscle IRS‐1 in Psammomys obesus , 2008, Diabetes/metabolism research and reviews.

[51]  L. Johnson,et al.  The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition , 1997, The EMBO journal.

[52]  H. Matter,et al.  Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.

[53]  Brian A. Hemmings,et al.  Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP , 2002, Nature Structural Biology.

[54]  Hua Tang,et al.  Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. , 2011, ACS chemical biology.

[55]  L. Pinna,et al.  How do protein kinases recognize their substrates? , 1996, Biochimica et biophysica acta.

[56]  M. Grdiša The delivery of biologically active (therapeutic) peptides and proteins into cells. , 2011, Current Medicinal Chemistry.

[57]  Emiko Fire,et al.  The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer , 2010, Nature chemical biology.

[58]  Roderick E Hubbard,et al.  Informatics and modeling challenges in fragment-based drug discovery. , 2007, Current opinion in drug discovery & development.

[59]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[60]  S. Knapp,et al.  Specificity Profiling of Pak Kinases Allows Identification of Novel Phosphorylation Sites* , 2007, Journal of Biological Chemistry.

[61]  Woody Sherman,et al.  Computational approaches for fragment-based and de novo design. , 2010, Current topics in medicinal chemistry.

[62]  Alexander D. MacKerell,et al.  Consideration of Molecular Weight during Compound Selection in Virtual Target-Based Database Screening , 2003, J. Chem. Inf. Comput. Sci..

[63]  Philip R. Cohen,et al.  Comparison of the specificities of p70 S6 kinase and MAPKAP kinase‐1 identifies a relatively specific substrate for p70 S6 kinase: the N‐terminal kinase domain of MAPKAP kinase‐1 is essential for peptide phosphorylation , 1995, FEBS letters.

[64]  M. Niv,et al.  BlockMaster: partitioning protein kinase structures using normal-mode analysis. , 2009, The journal of physical chemistry. A.

[65]  N. Xuong,et al.  A binary complex of the catalytic subunit of cAMP-dependent protein kinase and adenosine further defines conformational flexibility. , 1997, Structure.

[66]  M. Eisenstein,et al.  Computational mapping of anchoring spots on protein surfaces. , 2010, Journal of molecular biology.

[67]  M. Yaffe,et al.  A motif-based profile scanning approach for genome-wide prediction of signaling pathways , 2001, Nature Biotechnology.

[68]  Bostjan Kobe,et al.  The Predikin webserver: improved prediction of protein kinase peptide specificity using structural information , 2008, Nucleic Acids Res..

[69]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[70]  M. Verdonk,et al.  A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.

[71]  J. Audie,et al.  The synergistic use of computation, chemistry and biology to discover novel peptide-based drugs: the time is right. , 2010, Current pharmaceutical design.

[72]  Masha Y Niv,et al.  Peptidic modulators of protein‐protein interactions: Progress and challenges in computational design , 2009, Biopolymers.

[73]  P. Cohen,et al.  Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase‐1 and p70 S6 kinase , 1996, FEBS letters.

[74]  Toshiyuki Obata,et al.  Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB* , 2000, The Journal of Biological Chemistry.

[75]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[76]  Avraham Ben-Shimon,et al.  Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). , 2011, Journal of medicinal chemistry.

[77]  E. Krebs,et al.  Primary-structure requirements for inhibition by the heat-stable inhibitor of the cAMP-dependent protein kinase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[78]  S. Knapp,et al.  Structural and Functional Characterization of the Human Protein Kinase ASK1 , 2007, Structure.

[79]  Astrid Gräslund,et al.  Mechanisms of Cellular Uptake of Cell-Penetrating Peptides , 2011, Journal of biophysics.

[80]  Zhou Songyang,et al.  Determination of the Specific Substrate Sequence Motifs of Protein Kinase C Isozymes* , 1997, The Journal of Biological Chemistry.

[81]  J. Ferrell,et al.  Mechanisms of specificity in protein phosphorylation , 2007, Nature Reviews Molecular Cell Biology.

[82]  Ioannis Xenarios,et al.  T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension , 2011, Nucleic Acids Res..

[83]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[84]  J. Herrero,et al.  Exceptional Disfavor for Proline at the P+1 Position among AGC and CAMK Kinases Establishes Reciprocal Specificity between Them and the Proline-directed Kinases* , 2005, Journal of Biological Chemistry.

[85]  B. Werneburg,et al.  Pim kinase substrate identification and specificity. , 2006, Journal of biochemistry.

[86]  T. Soderling Structure and regulation of calcium/calmodulin-dependent protein kinases II and IV. , 1996, Biochimica et biophysica acta.

[87]  D. Knighton,et al.  2.0 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with a peptide inhibitor and detergent. , 1993, Acta crystallographica. Section D, Biological crystallography.

[88]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.